Glaxo agrees to pay $3 bil­lion to set­tle sev­eral probes

Modern Healthcare - - LATE NEWS -

Glax­o­smithk­line said it reached an agree­ment in prin­ci­ple to pay $3 bil­lion to set­tle a num­ber of in­ves­ti­ga­tions, in­clud­ing al­le­ga­tions the com­pany im­prop­erly mar­keted Avan­dia, its block­buster di­a­betes drug. The three in­ves­ti­ga­tions cited in a Glax­o­smithk­line state­ment in­clude a sales and mar­ket­ing in­ves­ti­ga­tion by U.S. at­tor­neys in Colorado and Mas­sachusetts and Jus­tice Depart­ment in­ves­ti­ga­tions into al­le­ga­tions of Med­i­caid fraud and the de­vel­op­ment and mar­ket­ing of Avan­dia. The fi­nal set­tle­ment, re­solv­ing civil and crim­i­nal li­a­bil­i­ties, is ex­pected to be made fi­nal next year, ac­cord­ing to Lon­don-based Glax­o­smithk­line. “This is a sig­nif­i­cant step to­ward re­solv­ing dif­fi­cult, long-

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.